Sarepta Therapeutics recently received FDA approval to resume shipments of ELEVIDYS for ambulatory patients after a temporary pause. The FDA’s recommendation to lift the voluntary hold on Elevidys marks a significant milestone for Sarepta Therapeutics, allowing the company to continue providing the gene therapy to patients in need. This decision follows a comprehensive review of safety information by the FDA, which determined that a recent death of a patient in Brazil was unlikely to be related to treatment with Elevidys. Doug Ingram, CEO of Sarepta Therapeutics, expressed satisfaction with the FDA’s swift action in completing the review and allowing the company to resume shipments. Moving forward, Sarepta can now focus on meeting the demand for Elevidys among ambulatory patients, with the company’s stock expected to experience a positive impact following this regulatory approval. This event highlights the importance of maintaining strong relationships with regulatory authorities in the pharmaceutical industry to ensure the success of future drug developments.
Read more from benzinga.com